All Press Releases

All Press Releases

HalioDx to Characterize the Immune Contexture of Patients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial

|   Science & Medicine

HalioDx’s immunoscoring technologies  to characterize patients treated with ImCheck’s investigational first-in-class…

Read more

First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy

|   Science & Medicine

-- First-in-human, international, multi-center trial to test Butyrophylin 3A-targeted antibody in advanced solid and…

Read more

ImCheck Therapeutics Expands Leadership Team with Appointment of Hans Henrik Chrois Christensen as Chief Financial Officer and Chief Operating Officer

|   Leadership & Corporate

-- Mr. Christensen adds financial, strategic and corporate development expertise to the ImCheck team --

Marseille,…

Read more

ImCheck Therapeutics is one of the 8 young French biotechs selected in the French Tech 120 program!

|   Leadership & Corporate

 

The French Tech revealed on January 20th the 83 most promising French startups for 2020 and ImCheck Therapeutics is…

Read more

ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases

|   Financial & Business

-- Bpifrance and Pfizer Ventures co-led international investor syndicate --

Marseille, France, December 04, 2019, 6:45…

Read more

ImCheck Therapeutics awarded €2 million from Bpifrance to advance its first-in-class immunotherapy program into the clinic

|   Financial & Business

Bpifrance views ImCheck’s projects as unique and well-positioned

ImCheck Therapeutics, a biotech company on the cutting…

Read more

ImCheck Therapeutics appoints Paul Frohna MD, PhD, PharmD, as Chief Medical Officer

|   Leadership & Corporate

Paul Frohna brings over 15 years of experience in translational medicine and clinical and regulatory strategy

ImCheck…

Read more

The French Région Sud and the European Union provide grant funding to Imcheck Therapeutics and its development of a new generation of cancer treatments

|   Financial & Business

Through a 717 K€ grant co-financed by the Région Sud and the European Union under the ERDF, ImCheck has received…

Read more

Award for ImCheck Therapeutics at the Aix-Marseille Innovation Awards

|   Leadership & Corporate

ImCheck Therapeutics awarded Innovation Start-up of the Year in Healthcare at the Aix-Marseille Innovation awards.

The…

Read more

ImCheck Therapeutics Appoints Prof. René Hoet, PhD, as Chief Scientific Officer

|   Leadership & Corporate

ImCheck Therapeutics, an emerging biopharmaceutical company developing novel immune modulators against cancer and…

Read more

ImCheck Therapeutics appoints Dr. Debasish Roychowdhury as its independent Chairman of the Board

|   Leadership & Corporate

With over a decade of patient care as a hematologist/oncologist and a career as a big pharma senior executive in R&D,…

Read more

ImCheck Therapeutics obtains 1M€ from Bpifrance to contribute to the development of a novel therapeutic antibody in immuno-oncology

|   Financial & Business

First non-dilutive funding received by ImCheck following its initial fundraising of 20 M€ in May 2017

Read more

ImCheck Therapeutics raises €20 Million and appoints its CEO

|   Financial & Business

Emerging leader in immuno-oncology accelerates its development programs and prepares for entry into the clinic

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter